Giant cell arteritis (GCA) is a medium and large vasculitis, wherein only glucocorticoids (GC) treatment has been the mainstay of therapy. As many will require prolonged treatment, the hazards of GC are well known, lead to substantial toxicity and morbidity.
All News
Sepsis is a dangerous and potentially fatal consequence of serious infections (SIE), particularly in susceptible populations such as the elderly and immunosuppressed. Published evidence points toward the potential role of TNF in development of sepsis.
A thoughtful perspective on the purpose, focus and cost of guideline efforts in rheumatology has been published in the journal Rheumatology.
Reuters and the Wall Street Journal have reported that the largest U.S. pharmacy benefit managers (PBM) of private prescription drug benefits have cut off at least eight pharmacies that work closely with drugmakers, intensifying scrutiny of a system that helps inflate drug prices.
Paine and Ritchlin have reviewed the evidence that new bone formation is centered around enthesial sites and that such findings are evident in psoriatic arthritis as well as psoriasis patients without arthritis.
Dr. Peter Taylor and colleagues presented their results of the 52-week BEAM trial wherein baricitinib (a JAK 1, 2 inhibitor) was compared to adalimumab in both clinical and radiographic outcomes. This was the most viewed abstract online at the ACR website.
Cacoub et al review the common entity cryoglobulinemic vasculitis (CryoVas) in the current issue of the American Journal of Medicine.
This small-vessel vasculitis involves the skin, joints, and potentially other organs, including the peripheral nervous system or the kidneys.
Furie and coworkers presented the results of a 52-week phase II trial of anifrolumab (ANIFR), a type I interfernon (IFN) receptor antagonist in patients with lupus (SLE).
Myasoedova and colleagues from the Mayo Clinic have reported their new data that demonstrates improving cardiovascular (CV) mortality rates in current RA patients treated with modern drugs.
ACR 2015 RA treatment guidelines were published yesterday, nearly a year after they were preliminarily presented at the 2014 ACR meeting in Boston. After a year of review and revision these have been posted.
Biosimilars are in the news and will be prominently on parade at next week's ACR meeting in San Francisco. Biosimilars are similar to, but not the same as, innovator biologics.
To assess the prevalence and magnitude of healthcare costs associated with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in the USA, researchers analyzed adminstrative data from Truven Health MarketScan Commercial and Medicare Supplemental databases.
Using Medicare claims data, a retrospective cohort study analyzed the risk of a second non-melanomatous skin cancer (NMSC) in 9460 individuals (6841 with RA and 2788 with IBD).
Rheumatology News reports the results of a novel trial presented at the European Academy of Dermatology and Venereology meeting in Copenhagen.
Despite concerns over safety, the FDA Arthritis Advisory Committee voted favorably to approve lesinurad (LES) at a meeting held Friday, October 23, 2015. Overall, panel members felt the potential benefits of LES outweighed the safety concerns reviewed by the FDA presenters.
The FDA has denied Pfizer's application seeking an indication for Xeljanz in patients with moderate to severe chronic plaque psoriasis.
Osteoporosis is associated with significant morbidity, and hip fractures as sequelae confer a 1-year mortality risk of 8.4–36%.
AMAGINE-2 and AMAGINE-3 are in two phase 3 studies that compare multiple doses of brodalumab (anti-IL-17) and ustekinumab (anti-12/23) in adults with moderate-to-severe psoriasis.
Biologic and new drug development seldom targets children and adolescents. This study evaluated the efficacy and safety of ustekinumab in adolescents age 12 to 17 years with moderate-to-severe psoriasis,
Mease and colleagues have published their results of a phase 3 trial of secukinumab (anti-IL-17A Mab) in 606 patients with psoriatic arthritis (PsA).
